Global Pharmaceuticals, Biotechnology & Life ... - Pharmavision

lunchlexicographerBiotechnology

Dec 1, 2012 (4 years and 10 months ago)

199 views


INDUSTRY PROFILE

Global Pharmaceuticals,
Biotechnology & Life
Sciences

Reference Code: 0199-2357
Publication Date: June 2010
CONTENTS

Global - Pharmaceuticals, Biotechnology & Life Sciences

0199 - 2357 - 2009
© Datamonitor. This profile is a licensed product and is not to be photocopied

Page 3

TABLE OF CONTENTS

EXECUTIVE SUMMARY 2

MARKET OVERVIEW 7

Market definition 7

Research highlights 8

Market analysis 9

MARKET VALUE 10

MARKET SEGMENTATION I 11

MARKET SEGMENTATION II 12

MARKET SHARE 13

FIVE FORCES ANALYSIS 14

Summary 14

Buyer power 16

Supplier power 18

New entrants 19

Substitutes 21

Rivalry 23

LEADING COMPANIES 24

Novartis AG 24

Pfizer Inc. 28

Roche Holding AG 32

Sanofi-Aventis SA 36

MARKET FORECASTS 40

Market value forecast 40

APPENDIX 42

Methodology 42

Industry associations 43

Related Datamonitor research 43

Disclaimer 44

CONTENTS

Global - Pharmaceuticals, Biotechnology & Life Sciences

0199 - 2357 - 2009
© Datamonitor. This profile is a licensed product and is not to be photocopied

Page 4

ABOUT DATAMONITOR 45

Premium Reports 45

Summary Reports 45

Datamonitor consulting 45

CONTENTS

Global - Pharmaceuticals, Biotechnology & Life Sciences

0199 - 2357 - 2009
© Datamonitor. This profile is a licensed product and is not to be photocopied

Page 5

LIST OF TABLES
Table 1:

Global pharmaceuticals, biotechnology & life sciences industry value: $ billion, 2005–09 10

Table 2:

Global pharmaceuticals, biotechnology & life sciences industry segmentation I:% share,
by value, 2009 11

Table 3:

Global pharmaceuticals, biotechnology & life sciences industry segmentation II: %
share, by value, 2009 12

Table 4:

Global pharmaceuticals, biotechnology & life sciences industry share: % share, by
value, 2009 13

Table 5:

Novartis AG: key facts 24

Table 6:

Novartis AG: key financials ($) 25

Table 7:

Novartis AG: key financial ratios 26

Table 8:

Pfizer Inc.: key facts 28

Table 9:

Pfizer Inc.: key financials ($) 29

Table 10:

Pfizer Inc.: key financial ratios 30

Table 11:

Roche Holding AG: key facts 32

Table 12:

Roche Holding AG: key financials ($) 33

Table 13:

Roche Holding AG: key financials (CHF) 34

Table 14:

Roche Holding AG: key financial ratios 34

Table 15:

Sanofi-Aventis SA: key facts 36

Table 16:

Sanofi-Aventis SA: key financials ($) 37

Table 17:

Sanofi-Aventis SA: key financials (€) 37

Table 18:

Sanofi-Aventis SA: key financial ratios 38

Table 19:

Global pharmaceuticals, biotechnology & life sciences industry value forecast: $ billion,
2009–14 40

CONTENTS

Global - Pharmaceuticals, Biotechnology & Life Sciences

0199 - 2357 - 2009
© Datamonitor. This profile is a licensed product and is not to be photocopied

Page 6

LIST OF FIGURES
Figure 1:

Global pharmaceuticals, biotechnology & life sciences industry value: $ billion, 2005–09 10

Figure 2:

Global pharmaceuticals, biotechnology & life sciences industry segmentation I:% share,
by value, 2009 11

Figure 3:

Global pharmaceuticals, biotechnology & life sciences industry segmentation II: %
share, by value, 2009 12

Figure 4:

Global pharmaceuticals, biotechnology & life sciences industry share: % share, by
value, 2009 13

Figure 5:

Forces driving competition in the global pharmaceuticals, biotechnology & life sciences
industry, 2009 14

Figure 6:

Drivers of buyer power in the global pharmaceuticals, biotechnology & life sciences
industry, 2009 16

Figure 7:

Drivers of supplier power in the global pharmaceuticals, biotechnology & life sciences
industry, 2009 18

Figure 8:

Factors influencing the likelihood of new entrants in the global pharmaceuticals,
biotechnology & life sciences industry, 2009 19

Figure 9:

Factors influencing the threat of substitutes in the global pharmaceuticals,
biotechnology & life sciences industry, 2009 21

Figure 10:

Drivers of degree of rivalry in the global pharmaceuticals, biotechnology & life sciences
industry, 2009 23

Figure 11:

Novartis AG: revenues & profitability 26

Figure 12:

Novartis AG: assets & liabilities 27

Figure 13:

Pfizer Inc.: revenues & profitability 30

Figure 14:

Pfizer Inc.: assets & liabilities 31

Figure 15:

Roche Holding AG: revenues & profitability 35

Figure 16:

Roche Holding AG: assets & liabilities 35

Figure 17:

Sanofi-Aventis SA: revenues & profitability 38

Figure 18:

Sanofi-Aventis SA: assets & liabilities 39

Figure 19:

Global pharmaceuticals, biotechnology & life sciences industry value forecast: $ billion,
2009–14 41

MARKET SEGMENTATION II

Global - Pharmaceuticals, Biotechnology & Life Sciences

0199 - 2357 - 2009
© Datamonitor. This profile is a licensed product and is not to be photocopied

Page 12

MARKET SEGMENTATION II
Americas accounts for 50.5% of the global pharmaceuticals, biotechnology & life sciences industry value.
Europe accounts for a further 25.7% of the global industry.

Table 3: Global pharmaceuticals, biotechnology & life sciences industry segmentation II: %
share, by value, 2009

Category
% Share
Americas 50.5%
Europe 25.7%
Asia-Pacific 18.2%
Rest of the World
5.7%
Total 100%
Source: Datamonitor D A T A M O N I T O R

Figure 3: Global pharmaceuticals, biotechnology & life sciences industry segmentation II: %
share, by value, 2009


Source: Datamonitor D A T A M O N I T O R
FIVE FORCES ANALYSIS

Global - Pharmaceuticals, Biotechnology & Life Sciences

0199 - 2357 - 2009
© Datamonitor. This profile is a licensed product and is not to be photocopied

Page 19

New entrants
Figure 8: Factors influencing the likelihood of new entrants in the global pharmaceuticals,
biotechnology & life sciences industry, 2009


Source: Datamonitor D A T A M O N I T O R

The nature of the markets tends to be high-risk, time-consuming and expensive. The profitability of
companies largely depends on technical expertise. A skilled work force is required, which contributes to
relatively high fixed costs in the market. Innovation remains a key determinant of the success or failure of
players in this highly competitive market. Stringent regulations exist in most countries regarding safety
and efficacy. In addition, many countries are witnessing reforms in order to control growing health care
costs. For example, in the US, government programs limit the amount of reimbursement they will pay for
certain procedures or treatments in order to reduce healthcare costs. Thus players must convince buyers
of the cost-effectiveness of their products. This process is time-consuming, expensive and usually
requires extensive clinical data. These reforms could limit the profit of pharmaceutical companies from the
generation of new drugs. In an effort to increase revenues, companies are beginning to exploit growing
markets in Asia-Pacific by pursuing some of the many pharmaceutical companies that operate in this
area. By doing so, market players may take advantage of less stringent regulations.



LEADING COMPANIES

Global - Pharmaceuticals, Biotechnology & Life Sciences

0199 - 2357 - 2009
© Datamonitor. This profile is a licensed product and is not to be photocopied

Page 26

Table 7: Novartis AG: key financial ratios

Ratio 2005 2006 2007 2008
2009
Profit margin 19.1% 19.5% 30.1% 19.9% 19.1%
Revenue growth 14.0% 14.9% 7.5% 4.2% 6.8%
Asset growth 6.0% 17.8% 10.9% 3.8% 22.0%
Liabilities growth 19.6% 8.7% (2.5%) 6.9% 36.5%
Debt/asset ratio 42.6% 39.3% 34.5% 35.6% 39.8%
Return on assets 10.9% 11.5% 16.7% 10.7% 9.7%
Revenue per employee $354,274 $367,499 $405,295 $428,663 $443,406
Profit per employee $67,540 $71,495 $121,874 $85,125 $84,681

Source: company filings D A T A M O N I T O R

Figure 11: Novartis AG: revenues & profitability


Source: company filings D A T A M O N I T O R